GILD News | Roxom Stocks

Invest Private Security

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Preferreds paying dividends in bitcoin.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Everything Roxom publishes, in one feed.

Product launches, listings, and company news.

Commentary and analysis from the Roxom team.

Research Reports

In-depth research on bitcoin capital markets.

Weekly market updates, delivered to your inbox.

Roxom in the news, and press resources.

Where to find us, online and in person.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

GI

Mkt Cap

$187.28B

Volume

1.72M

Next Earnings

October 29th

Loading chart

GI

GILDGilead Sciences Inc

GILD

Pay with—

Available Balance0.00

GI

Mkt Cap

$186.13B

Volume

1.72M

Next Earnings

October 29th

Chart Financials Earnings News About Dividends Insider Filings

Can AstraZeneca's Broad Pipeline Offset Recent Setbacks?AstraZeneca's stock has declined following several late-stage pipeline failures including Wainua in ATTR-CM, Ultomiris in HSCT-TMA, volrustomig in NSCLC, and Etcamah in breast cancer. However, the company maintains a broad pipeline with over 20 expected high-value readouts in the next 18 months, particularly in oncology. The stock trades at a reasonable valuation of 16.29x forward earnings, below industry average, though 2026-2027 earnings estimates have been revised downward.Zacks Investment Research · Sep 18, 2026

J&J Up 18% in Three Months: Buy, Sell or Hold the Stock?Johnson & Johnson's stock has risen 18.3% in three months, driven by strong Innovative Medicine segment growth (6.2% organic), successful new drug launches (Icotyde, Imaavy, Inlexzo), and progress on talc litigation resolution. The company targets $100 billion in 2026 revenues and expects double-digit growth excluding Stelara impact. However, J&J faces headwinds from Stelara's patent expiration, MedTech slowdown, and upcoming generic competition for other drugs. Despite these challenges, analysts recommend staying invested given the company's diversified portfolio, strong pipeline, and confident guidance.Zacks Investment Research · Sep 18, 2026

Should You Invest in the VanEck Biotech ETF (BBH)?The VanEck Biotech ETF (BBH) offers low-cost exposure to the biotech sector with a 0.35% expense ratio and $462.7 million in assets. The fund tracks the MVIS US Listed Biotech 25 Index and holds 26 companies with top holdings including Amgen, Gilead Sciences, and Vertex Pharmaceuticals. BBH has returned 21.89% year-to-date and 39.46% over the past year, but carries higher risk with a beta of 0.70 and 19.89% standard deviation. The fund received a Zacks ETF Rank of 2 (Buy).Zacks Investment Research · Sep 16, 2026

CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma Market Set for Expansion Through 2036, Fueled by Treatment Innovation and Rising Patient DemandThe CAR T-cell therapy market for non-Hodgkin's lymphoma is projected to grow at a 7% CAGR from 2026 to 2036, reaching from a 2025 valuation of $3.20 billion across seven major markets. Growth is driven by broader clinical adoption, new indications, earlier-line use, and innovation in autologous and allogeneic platforms. The U.S. dominates with $1.90 billion in 2025 market value, while diffuse large B-cell lymphoma represents the largest patient population with approximately 78,000 cases across the markets.GlobeNewswire Inc. · Sep 16, 2026

CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Market Set for Strong Growth Through 2036, Driven by Next-Generation Innovation and Expanding Patient AccessThe CAR-T cell therapy market for acute lymphoblastic leukemia (ALL) is projected to grow at a 6.8% CAGR from 2026 to 2036, reaching from $300 million in 2025. The market is driven by approved therapies like KYMRIAH, TECARTUS, and AUCATZYL, with emerging innovations including allogeneic platforms and CD7-targeting therapies. Key challenges include relapse rates, manufacturing complexity, and toxicity management, while opportunities exist in earlier treatment lines and off-the-shelf platforms.GlobeNewswire Inc. · Sep 16, 2026

GSK's Specialty Medicines Drive Growth Amid Looming HIV Patent CliffGSK's Specialty Medicines segment, accounting for over 40% of sales, grew 14% in H1 2026 driven by HIV, respiratory, and oncology products. The company is accelerating R&D with over 20 phase III starts planned for 2026. However, GSK faces a significant challenge as dolutegravir patents expire in 2028-2029, threatening its HIV franchise which generated £2.74 billion in H1 2026. GSK is relying on long-acting HIV injectables and next-generation pipeline products to offset future generic competition.Zacks Investment Research · Sep 10, 2026

Will The Recent Pipeline Progress Boost BMY's Portfolio Expansion?Bristol Myers Squibb announced positive Phase II results for arlo-cel, a first-in-class GPRC5D-directed CAR T cell therapy, in heavily pretreated multiple myeloma patients. The QUINTESSENTIAL study met its primary endpoint showing statistically significant overall response rates in quadruple-class exposed patients. This positions BMY to treat patients resistant to BCMA-directed therapies, broadening its multiple myeloma portfolio alongside recently approved Zenbexus.Zacks Investment Research · Sep 9, 2026

Monoclonal Antibodies Market to Grow at 11.01% CAGR, Reaching USD 791.28 Billion by 2035 – SNS InsiderThe global monoclonal antibodies market is projected to grow from USD 280.15 billion in 2025 to USD 791.28 billion by 2035, driven by increasing demand for targeted therapies in oncology, autoimmune disorders, and chronic diseases. North America leads with 41% market share, while Asia-Pacific shows the fastest growth at 12.32% CAGR. Key innovations include bispecific antibodies and antibody-drug conjugates, with humanized antibodies emerging as the fastest-growing segment.GlobeNewswire Inc. · Sep 9, 2026

Chronic Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Domain | DelveInsightThe chronic myeloid leukemia (CML) clinical trial pipeline shows robust activity with 25+ pharmaceutical companies developing 25+ pipeline drugs. Key players including Merck, Enliven Therapeutics, ImmunoForge, and others are advancing promising therapies like TERN-701, ELVN-001, and KF1601 across various clinical stages. The market is evolving from established tyrosine kinase inhibitors toward newer selective agents targeting resistance, intolerance, and treatment-free remission.GlobeNewswire Inc. · Sep 8, 2026

Unlocking Opportunity: Dominate the Market of CAR/TCR/TIL Therapies in Oncology with Confidence. See Exactly How Gilead, Cellectis, MediGene, GenScript, and CARsgen Are Positioned to Win Through 870+ RivalsResearchAndMarkets.com released a comprehensive analytical tool tracking CAR/TCR/TIL therapies in oncology, monitoring 870+ organizations and 2,370+ drugs across the pipeline. The tool provides competitive intelligence on leading developers including Gilead Sciences, Cellectis, MediGene, GenScript, and CARsgen Therapeutics, with 236 new therapies added in 2024/25 and over 1,700 BD&L contacts for partnership opportunities.GlobeNewswire Inc. · Sep 7, 2026

to start trading

GI

GILDGilead Sciences Inc

GILD

Pay with—

Available Balance0.00

Your PositionYou don't own any GILD yet.

Related Tickers

Earnings

Dividends

Last · Sep 15Quarterly

Amount$0.82

Yield2.15%

Annual$3.25